drugset / Trial / NCT00264537

A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive

NCT00264537

Phase 3 Completed 637 enrolled Centocor, Inc. Schering-Plough · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of golimumab, alone or in combination with methotrexate, as compared to methotrexate alone in rheumatoid arthritis subjects who have not been previously treated with methotrexate.

Timeline

Start
2005-12
Primary completion
2008-04
Completion
2012-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Golimumab Monoclonal antibody 50 mg Subcutaneous
Subject Golimumab Monoclonal antibody 100 mg Subcutaneous
Subject Methotrexate Small molecule 10 mg
Subject Methotrexate Small molecule 20 mg

Indications